Quotables
"There is practically no chance communications space satellites will be used to provide better telephone, telegraph, television, or radio service inside the United States."
T. Craven, FCC Commissioner ; 1961
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7759467 | Enhanced mediated DNA transfer A method to increase the efficiency of transduction of hematopoietic and other cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. The fibronectin and fibronectin fragments significantly enhance retroviral-medi... | 07/20/2010 |
| 7667006 | Anti-HIV antibody The present invention aims at providing a high affinity anti-HIV antibody. According to the present invention, there are provided an antibody or a fragment thereof that binds to the gp12 glycoprotein of HIV and has a dissociation constant (KD) value of 1.0×10â... | 02/23/2010 |
| 7531642 | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26). The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared... | 05/12/2009 |
| 7531639 | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26) The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared... | 05/12/2009 |
| 7531641 | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26) The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared... | 05/12/2009 |
| 7531638 | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26) The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared... | 05/12/2009 |
| 7531640 | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26) The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared... | 05/12/2009 |
| 7528238 | Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26) The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared... | 05/05/2009 |
| 7326416 | Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1(INI1)/hSNF5 Peptides comprising an Rpt1 domain of an INI1/hSNF5 which inhibit HIV-1 production in a human cell, and vectors encoding those peptides are provided. Also provided are methods of inhibiting HIV-1 production in a cell, or spread of the HIV-1 to another cell, by treat... | 02/05/2008 |
| 7311920 | Virus coat protein/receptor chimeras and methods of use The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can interact with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties charact... | 12/25/2007 |
| 7223844 | Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexes The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4, and pharmaceutical compositions comprising the antibodies or antibody ... | 05/29/2007 |
| 7189826 | Monoclonal human natural antibodies Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and m... | 03/13/2007 |
| 7157091 | MAGE-A1 peptides presented by HLA class II molecules The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0–10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal co... | 01/02/2007 |
| 7122638 | Monoclonal human natural antibodies Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and m... | 10/17/2006 |
| 7060281 | Groups of and that cause lyme disease in humans The present invention is drawn to an immunogenic composition comprising OspC polypeptides from Lyme Disease causing Borrelia. In one embodiment, the immunogenic composition of the present invention comprises at least one OspC polypeptide or immunogenic fragme... | 06/13/2006 |
| 7056735 | Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator) The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleot... | 06/06/2006 |
| 7041293 | HIV env antibodies The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/g120 binding and reduce reverse transcriptase activity in vitro. ... | 05/09/2006 |
| 7033593 | Immunogen comprising an HIV envelope protein, a ligand and H2 peptide The invention relates to an immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4 binding site and the CCR5 binding site on the protein, and bound to an HR-2 peptide. The invention also relates to a method o... | 04/25/2006 |
| 7018633 | Selective destruction of cells infected with human immunodeficiency virus Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a varient of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of ... | 03/28/2006 |
| 7008622 | Methods and compositions for impairing multiplication of HIV-1 A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and... | 03/07/2006 |
| 6908734 | Sulfated CCR5 peptides for HIV-1 infection This invention provides a compound comprising the structure: θαYDINYYTSEβλ wherein each T represents a threonine, each S represents a serine, each E represents a glutamic acid, each Y represents a tyrosine; each D represents an aspartic acid, each I represents a... | 06/21/2005 |
| 6818392 | Monoclonal antibodies to human immunodeficiency virus and uses thereof The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared... | 11/16/2004 |
| 6815201 | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies The invention features a protein which includes a gp120 V1/V2 domain of an HIV-1 strain and not a gp120 V3 domain of an HIV-1 strain, which protein does not substantially bind CD4. The gp120 V1/V2 domain of the protein displays an epitope which is recognized by an a... | 11/09/2004 |
| 6737267 | Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates, and uses thereof This invention provides an immunoconjugate which comprises 1) a non-peptidyl toxin and 2) a CD4-gamma2 chimeric heavy chain homodimer linked thereto. This invention also provides an immunoconjugate which comprises 1) a gamma radiation-emitting radionuclide of low to... | 05/18/2004 |
| 6733993 | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to ... | 05/11/2004 |
| 6709811 | Versatile reagent for detecting murine leukemia viruses A method for detecting broad spectrum of murine leukemia viruses belonging to any or all of the ecotropic, xenotropic, polytropic and amphotropic groups, has been described. The method utilizes a monoclonal antibody designated 83A25 which identifies almost all class... | 03/23/2004 |
| 6670181 | Compositions and methods for treating viral infections Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential e... | 12/30/2003 |
| 6670466 | Human endogenous retrovirus in breast cancer The present invention is related to mammary tumor virus (MTV). MTV represents a group of retroviruses which possess very high homology to mouse mammary tumor virus (MMTV), a virus known to cause neoplastic mammary disease in mice. As described herein, MTV... | 12/30/2003 |
| 6657050 | Chimeric viral-neutralizing immunoglobulins Chimeral viral-neutralizing, particularly HIV-neutralizing, immunoglobulins made up of a non-human antigen binding region and a human constant region are described.... | 12/02/2003 |
| 6610833 | Monoclonal human natural antibodies Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formula... | 08/26/2003 |
| 6608179 | Antibodies, that bind to HIV-2 transmembrane glycoprotein homodimer (gp 80) Characterization of the envelope transmembrane protein of human immunodeficiency virus type 2 (HIV-2) was carried out using murine polyclonal and monoclonal antibodies or patient sera specific for HIV-2 proteins. A 80-Mr glycoprotein (gp80) was produced i... | 08/19/2003 |
| 6600023 | Antibody directed against HIV-1 P25 antigen Antibodies which bind with antigens of human immunodeficiency virus type 1 (HIV-1), such as Lymphadenopathy Associated Virus (LAV), are disclosed. Retroviruses associated with Acquired Immune Deficiency Syndrome (AIDS) are isolated from the sera of patien... | 07/29/2003 |
| 6579527 | Feline immunodeficiency virus nucleotide sequence This invention relates to a highly cytopathic and infectious clone constructed from the genomic DNA of a cat FIV. The nucleotide sequences of the infectious clone is disclosed. The nucleotide sequence, and peptides derived therefrom can be used in the det... | 06/17/2003 |
| 6557296 | Non-infectious, protease defective HIV particles and nucleic acid molecules encoding therefor This invention is directed toward mutated DNA, proteins, or protein fragments and particles from the L-2 cell line. The invention is also directed to diagnostic, prophylactic and therapeutic methods of making and using the DNA, proteins and particles.... | 05/06/2003 |
| 6528626 | Retrovirus from the HIV group and its use A novel immunodeficiency virus is disclosed which has the designation MVP-5180/91 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 920 52 318. The characteristic antigens which can be obtained from it a... | 03/04/2003 |
| 6525179 | Methods and compositions for impairing multiplication of HIV-1 A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus se... | 02/25/2003 |
| 6509018 | Non-M non-O HIV strains, fragments and uses The invention provides peptides which are expressed by the env gene of a non-M, non-O HIV-1 virus, in particular a strain designated YBF30. The invention also provides fragments of the peptides that including the V3 loop region and their corresponding nuc... | 01/21/2003 |
| 6489449 | Peptides for inhibition of HIV infection The present invention relates to peptides that can inhibit the infection of HIV, and more particularly, to peptides consisting of less than 30 amino acids which can introduce a helix capping motif into a peptide derived from C-terminal helical region (its... | 12/03/2002 |
| 6479284 | Humanized antibody and uses thereof A humanized antibody framework motif is described. Preferably, the motif is encoded by the VH gene of K5B8 and the VL gene of TR1.6. This humanized antibody preferably contains the variable region of a tat antibody.... | 11/12/2002 |
| 6455492 | Hepatitis E virus vaccine and method Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reasing frames of the H... | 09/24/2002 |
